32. ADDRESSING METHODOLOGICAL CHALLENGES IN CIAS TO ENHANCE CLINICAL TRIAL SUCCESS

摘要

Cognitive impairment is common in patients with schizophrenia, with deficits frequently observed across both neurocognitive and social cognitive tasks. Cognitive dysfunction is among the strongest determinants of poor social and occupational functioning in this population, indicating that these deficits represent an important unmet target for therapeutic intervention. Despite considerable efforts by pharmaceutical companies, there are currently no drugs that have been approved for the amelioration of these deficits in schizophrenia. A series of compounds have demonstrated early promise, only to have failed at the later stages of development. It remains a matter of debate whether this is truly due to the compounds being ineffective, or whether trial methodology itself has been a limiting factor in successfully demonstrating the efficacy of these agents.